Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. UBX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
UBX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

UBX Similar Chart Price Prediction

The price of UBX is predicted to go up -11.79%, based on the high correlation periods with WD. The similarity of these two price pattern on the periods is 97.98%.

stocks logo

UBX

stocks logo

WD

Down: -11.79%Similarity: 97.98%

UBX Revenue Forecast

UBX EPS Forecast

UBX FAQs

What is bull’s view on UBX?

UBX stock is currently trading at $1.39, with analysts projecting a significant upside to $6.00, driven by the potential of its lead candidate UBX1325 in treating diabetic macular edema. The recent appointment of Federico Grossi as Chief Medical Officer has bolstered investor confidence, reflected in a 9% pre-market gain following the announcement. With a bullish put/call ratio and institutional support, the stock shows strong momentum for growth.

What is bear's view on UBX?

UBX stock is currently trading at $1.54, and bears may argue that its financial health is weak, with no projected revenue and a negative EPS of -5.73. Institutional ownership has slightly decreased, signaling reduced confidence among major investors. Additionally, despite recent positive developments, the stock's speculative nature and reliance on clinical trial outcomes make it highly risky.

What is UBX eps forecast for next quarter？

The market consensus for UBX's eps in the upcoming quarter is projected to be approximately $0.31 USD.

UBX VS S&P500

Ask Intellectia about UBX

UBX Analyst's Forecast

Daniil Gataulin

Chardan Capital

Strong Buy

Price Target

$6

Upside

+235.2%

Chardan initiated coverage of Unity Biotechnology with a Buy rating and $6 price target. The company's lead candidate UBX1325 is currently being investigated in the Phase 2b ASPIRE trial in treatment-experienced diabetic macular edema patients, with topline data expected in Q1 of 2025, notes the analyst, who bases the firm's rating and target on the potential of UBX1325 in DME.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free